Search Within

David Solit

Formats
  1. Meeting Abstract (391)
  2. Journal Article (366)
  3. Editorial (9)
  4. Book Section (4)
  5. Research Letter (4)
  6. Review (4)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (783)
  2. GSK Faculty (783)
  3. Genitourinary Oncology Service (783)
  4. Human Oncology and Pathogenesis Program (783)
  5. Solid Tumor Oncology Division (783)
  6. Department of Pathology and Laboratory Medicine (510)

More Groups

People
  1. Michael Berger (317)
  2. Hikmat Al-Ahmadie (186)
  3. Gopakumar Iyer (184)
  4. Neal Rosen (155)
  5. Nikolaus Schultz (150)
  6. Dean Bajorin (130)

More People

Years
  1. 2025 (17)
  2. 2024 (38)
  3. 2023 (39)
  4. 2022 (44)
  5. 2021 (47)
  6. 2020 (59)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (99)
  3. Clinical Cancer Research (77)
  4. Laboratory Investigation (42)
  5. Modern Pathology (37)
  6. Cancer Discovery (24)

More Publications

Publishers
  1. American Association for Cancer Research (219)
  2. American Society of Clinical Oncology (181)
  3. Nature Publishing Group (97)
  4. Nature Research (39)
  5. Elsevier Inc. (31)
  6. Oxford University Press (29)

More Publishers

Results (783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors
    Journal Article

    Yang, S.; Qu, S.; Perez-Tores, M.; Sawai, A.; Rosen, N.; Solit, D. B.; Arteaga, C. L.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Hsp90: A novel target for cancer therapy
    Journal Article

    Solit, D. B.; Rosen, N.
    Current Topics in Medicinal Chemistry (2006)

    Fulltext@MSK | Save
  • BRAF mutation predicts sensitivity to MEK inhibition
    Journal Article

    Solit, D. B.; Garraway, L. A.; Pratilas, C. A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J. M.; She, Y.; Osman, I.; more...
    Nature (2006)

    Fulltext@MSK | Save
  • Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET
    Journal Article

    Smith-Jones, P. M.; Solit, D.; Afroze, F.; Rosen, N.; Larson, S. M.
    Journal of Nuclear Medicine (2006)

    Fulltext@MSK | Save
  • mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    Journal Article

    O'reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
    Journal Article

    Grbovic, O. M.; Basso, A. D.; Sawai, A.; Ye, Q.; Friedlander, P.; Solit, D.; Rosen, N.
    Proceedings of the National Academy of Sciences of the United States of America (2006)

    Fulltext@MSK | Save
  • Heat shock protein-90 inhibitors: A chronicle from geldanamycin to today's agents
    Journal Article

    Chiosis, G.; Lopes, E. C.; Solit, D.
    Current Opinion in Investigational Drugs (2006)

    Fulltext@MSK | Save
  • Combined inhibition of PI3 kinase and EGFR overcomes the intrinsic apoptosis resistance of PTEN-null cancer cells and suppresses their xenograft growth
    Meeting Abstract

    She, Q. B.; Solit, D.; Ye, Q.; O'reilly, K.; Rosen, N.
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Cyclin D expression and G1 progression are dependent on MEK MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras and Raf
    Meeting Abstract

    Sawai, A.; Pratilas, C.; Basso, A.; Rosen, N.; Solit, D. B.
    Cancer Research (2005)

    Fulltext@MSK | Save